Cardiovascular Systems Inc

Cardiovascular Systems — Q1 FY2023 Earnings Presentation

12 slides from Cardiovascular Systems's earnings presentation, Nov 3, 2022

  1. Slide 1: Q1 FY23 Earnings Supplement

    ©2022 Cardiovascular Systems, Inc. All Rights Reserved. Q1 FY23 Earnings Supplement November 3, 2022

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Report Act of 1995, which are provided under the protection of the safe harbor for forward-looking statements provided by that Act. For example, statements in this presentation r

  3. Slide 3: Q1 FY23 Highlights: Worldwide Revenue of $59.7 Million

    2.2% increase Y/Y Q1 FY23 Worldwide Revenue of $59.7 Million Q1 FY23 Revenue Breakdown Worldwide Peripheral $38.8 -4.8% Q/Q -0.6% Y/Y Worldwide Coronary $20.9 -4.0% Q/Q 7.9% Y/Y Worldwide Peripheral Worldwide Coronary ($ in millions, Q/Q and Y/Y represent Quarter-over-Quarter and Year-over-Year grow

  4. Slide 4: Q1 FY23: U.S. Peripheral

    Q1 FY23: U.S. Peripheral 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue 2 Includes peripheral orbital atherectomy devices, ViperWire, ViperSlide, Exchangeable cartridges, ViperTrack and other 3 Zilient Guidewires, Shepherd Guidewires, JADE angioplasty

  5. Slide 5: Q1 FY23: U.S. Coronary

    Q1 FY23: U.S. Coronary 1 Is the total of Orbital Atherectomy System Revenue plus Interventional Support Device Revenue 2 Includes Diamondback, Coronary Guidewire, ViperSlide and other 3 Includes Sapphire angioplasty balloons, Teleport microcatheters and Scoreflex NC balloons 1.3% Y/Y growth driven b

  6. Slide 6: Q1 FY23: International

    Q1 FY23: International 39.6% Y/Y revenue growth driven by Japan and EU coronary 6 Revenue decreased 7.2% Q/Q and increased 39.6% Y/Y • International revenue of $4.6 million driven by: • Japan, where revenue increased 20.3% Y/Y • Europe, where revenue increased 159.0% Y/Y • Certified over 80 new phys

  7. Slide 7: Q1 FY23 vs. Q4 FY22 and Q1 FY22

    Q1 FY23 vs. Q4 FY22 and Q1 FY22 Dollars in thousands 7 Q1 FY23 Quarter/Quarter Change Year/Year Change Worldwide Revenue $59,673 -4.5% 2.2% Worldwide Peripheral Revenue $38,784 -4.8% -0.6% Worldwide Coronary Revenue $20,889 -4.0% 7.9% U.S. Revenue $55,027 -4.3% 0.0% U.S. Peripheral Revenue $38,649 -

  8. Slide 8: Q1 FY23: Select Financial Information

    Q1 FY23: Select Financial Information Dollars in thousands, except earnings per share and shares outstanding 8 Q1 FY23 Q4 FY22 Q/Q Change Fav (Unfav) Q1 FY22 Y/Y Change Fav (Unfav) Net revenues $59,673 $62,496 ($2,823) $58,370 $1,303 Cost of goods sold 16,698 16,269 (429) 14,308 (2,390) Gross Margin

  9. Slide 9: Reiterating FY23: Annual Guidance

    Reiterating FY23: Annual Guidance 9 For the fiscal year ending June 30, 2023, CSI anticipates: Revenue of $255 million to $265 million; Gross profit as a percentage of revenues of 72% to 74%; Net loss in a range of 9% to 11% of revenues; and Adjusted EBITDA near break-even. Research and development

  10. Slide 10: Non-GAAP Financial Measures

    Non-GAAP Financial Measures 10 CSI uses Adjusted EBITDA as a supplemental measure of performance and believes this measure facilitates operating performance comparisons from period to period and company to company by factoring out potential differences caused by depreciation and amortization expense

  11. Slide 11: Investor Contact

    Investor Contact: Jack Nielsen Vice President, Investor Relations & Corporate Communications 651-202-4919 j.nielsen@csi360.com CSI®, Diamondback®, Diamondback 360®, Shepherd™, ViperCath™, ViperCross™, ViperSlide®, ViperTrack®, ViperWire®, ViperWire Advance®, Wirion® and Zilient® are trademarks of Ca

  12. Slide 12: Cardiovascular Systems, Inc.

    CARDIOVASCULAR SYSTEMS, INC. cS. www.csi360.com

Cardiovascular Systems — Q1 FY2023 Earnings Presentation on 6ix